MetrioPharm AG, a clinical stage pharmaceutical biotech company developing new medications against chronic inflammatory diseases, today announces the presentation of preclinical data related to multiple sclerosis (MS) and the company’s lead-compound MP1032 at the 34th ECTRIMS Congress. This congress is organized by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and represents the world’s largest annual international meeting devoted to basic and clinical research in MS. Read more